ADMA BIOLOGICS, INC. (NASDAQ:ADMA) Files An 8-K Other Events
Item 8.01
On July 2, 2019, the Food and Drug Administration notified ADMA Biologics, Inc. (the “Company”) that the licenses for BIVIGAM® and Nabi-HB® have been revoked from Biotest Pharmaceuticals Corporation and transferred and issued to the Company. On July 8, 2019, the Company issued a press release entitled “ADMA Biologics Receives FDA Approval for License Transfers for BIVIGAM® and Nabi-HB®.” The full text of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
(d) Exhibits
| 99.1 | Press release dated July 8, 2019, entitled “ADMA Biologics Receives FDA Approval for License Transfers for BIVIGAM® and Nabi-HB®.” |
ADMA BIOLOGICS, INC. Exhibit
EX-99.1 2 e618545_ex99-1.htm Exhibit 99.1 ADMA Biologics Receives FDA Approval for License Transfers for BIVIGAM® and Nabi-HB® All Aspects of the Biotest Therapy Business Unit (“BTBU”) Acquisition Are Successfully Completed RAMSEY,…
To view the full exhibit click here
About ADMA BIOLOGICS, INC. (NASDAQ:ADMA)
ADMA Biologics, Inc. is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics. Its segments include Plasma Collection Centers, which includes its operations in Georgia; Research and Development, which includes its plasma development operations in New Jersey, and Corporate. Its targeted patient populations are immune-compromised individuals suffering from an underlying immune deficiency disorder or may be immune-suppressed for medical reasons. Its product candidates are intended to be used by physician specialists focused on caring for immune-compromised patients at risk of contracting infectious diseases. Its intravenous immunoglobulin product candidate, RI-002, is intended for the treatment of primary immune deficiency disease.